However, Mr. Papa’s plan to regain stability and ensure Valeant’s ability to repay debt did not reassure investors.
The company’s first quarter earnings — the last set of financial results under former CEO J. Michael Pearson — showed two of Valeant’s key categories, dermatology and prescription ophthalmology, declined by 43 percent and 40 percent, respectively, according to the report.
On Tuesday morning at 9:11 a.m., shares were down 18 percent to $23.54 before the markets opened in New York
Valeant’s turnaround will be a “multi-year process,” Mr. Papa said on a phone call with analysts Tuesday, according to Bloomberg. “We have a stabilization plan and we will execute on this plan. We’ve hit a few speed bumps.”
Earnings this year will be between $6.60 and $7 a share, excluding certain items, Valeant said in a statement Tuesday. In March, under Mr. Pearson’s leadership, the company anticipated earnings of $8.50 to $9.50 per share. Analysts were predicting earnings of $8.49 a share, according to Bloomberg. In the first quarter, earnings of $1.27 missed analysts’ predictions by 10 cents.
Mr. Papa said he expects it to take three to six months to stabilize the company before it embarks on a long-term, comprehensive transformation. He said the company will also divest some non-core assets, according to the report.
More articles on supply chain:
Hospitals give ‘baby boxes’ a try, ripping a page from Finland’s playbook
NuVasive acquires Biotronic for $98M
Medtronic to launch new surgical robot by 2019
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
